General News Oxurion NV: Key developments and timeline for current the potential acquisition EN FR NL 5 days ago
General News Important Advances in Oxurion’s R&D Program on Geographic Atrophy secondary to AMD EN NL FR May 6, 2024
General News Oxurion Receives EUR 450,000 in the framework of the Atlas Funding Program : Eleventh tranche fully issued and paid-up EN FR April 10, 2024
General News OXURION announces its presence at the Paris SmallCap event on March 28, 2024. EN FR March 25, 2024
General News Oxurion Receives EUR 300,000 in the framework of the Atlas Funding Program Tenth tranche fully issued and paid-up EN FR March 5, 2024
General News Oxurion Receives EUR 850,000 in the framework of the Atlas Funding Program Eight and ninth tranches fully issued and paid-up EN FR February 14, 2024
General News Oxurion Announces New Strategic Orientation to De-risk and Diversify EN NL FR January 22, 2024
General News Regulated Oxurion Avoids Bankruptcy, Announces Board and Management Changes and Enters into Binding Letter of Intent with its Main Creditor Atlas EN NL December 28, 2023
General News Oxurion Receives EUR 1.0 Million under Amended Atlas Funding Program Total of EUR 3.5 Million in Unconditional Funding Allowing Company to Reach Topline Data from KALAHARI Trial This Year EN November 16, 2023
General News Oxurion Receives EUR 1.5 Million under Amended Atlas Funding Program; Total of EUR 3.5 Million in Unconditional Funding Allowing Company to Achieve Topline Data from KALAHARI Trial EN October 25, 2023
General News Oxurion Receives First EUR 1 Million under Amended Atlas Funding Program EN September 18, 2023
General News Oxurion Receives Funding of EUR One Million under Atlas Special Opportunities LLC (Atlas) Funding Program EN August 11, 2023
General News Oxurion Receives Upfront Payment of $400,000 Following Oncurious Asset License by VIB EN July 25, 2023
General News Oxurion Issues EUR 1.0 million in Bonds for Tranche 3 of the Funding Program with Atlas Special Opportunities LLC EN June 15, 2023
General News Oxurion Finalizes Enrollment in KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema EN June 12, 2023
General News Regulated Oxurion Reaches Enrollment Target in KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema EN May 25, 2023